O'Dell Group’s Teva Pharmaceuticals TEVA Stock Holding History

O'Dell Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25	Closed	–	–	578
2021 Q4	$0	Hold	25	–	–	﹤0.01%	545
2021 Q3	$0	Buy	+25	New	+$234	﹤0.01%	504

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

O'Dell Group's TEVA Position: Q1 2022 in Review

O'Dell Group sold out of Teva Pharmaceuticals (TEVA) in Q1 2022, closing a stake of 25 shares.

O'Dell Group first reported a position in TEVA in Q3 2021 and held it in 2 quarters. The position peaked at $0 in Q4 2021. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2022.

O'Dell Group reported no remaining Teva Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
O'Dell Group sold 25 Teva Pharmaceuticals shares in Q1 2022.
O'Dell Group first reported a position in Teva Pharmaceuticals in Q3 2021 and held it in 2 quarters.
O'Dell Group's Teva Pharmaceuticals position peaked at $0 in Q4 2021.
438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2022.

Based on O'Dell Group's 13F filing for Q1 2022, filed 5 May 2022.